AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$GILD

O'Day Daniel Patrick sold $1.4M of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 10,900 shares of GILEAD SCIENCES, INC. (GILD) at $131.10 ($1.43M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Day Daniel Patrick
Published Jun 2, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GILD
Neutral
medium confidence
Mentioned
$GILD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

Provides a datapoint on insider liquidity/positioning but does not, by itself, change the company’s fundamental outlook.

02

Market read

Traders may briefly reassess sentiment around GILD, but 10b5-1 framing typically limits the magnitude and duration of any reaction.

03

What to watch

The article doesn’t state whether the sale was part of a larger series, tax-related liquidity needs, or whether other insiders/funds were buying; without that context, signal quality is weak.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/next session disclosure (2026-06-02 filing; sale dated 2026-06-01).

Background

The filing is an SEC Form 4 insider transaction: CEO/Chairman O'Day sold shares under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$GILDNeutralMedium confidence
Context

Gilead CEO/Chairman O'Day sold 10,900 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Likely minimal near-term price impact; any reaction should be small and quickly mean-reverting unless accompanied by other news.

Evidence & confidence

The filing provides a concrete datapoint (sale size/price) but does not indicate a new operational/regulatory catalyst; 10b5-1 typically dampens interpretive value.

Market effects

Sector

Limited read-through to biotech/large-cap pharma; this is company-specific insider activity without stated sector catalyst.

Regional

No clear regional spillover expected from a single 10b5-1 insider sale.

Global

Minimal global relevance; disclosure is US SEC Form 4 with no associated international event described.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated or sizable insider selling can still coincide with internal caution; traders may watch for follow-on sales or changes in plan behavior.

Key entities

  • issuer
    Gilead Sciences, Inc.

    Subject of the SEC Form 4 insider sale disclosed on 2026-06-02.

  • insider
    O'Day Daniel Patrick

    Chairman & CEO who executed the open-market sale (10,900 shares) on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$GILDMed

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.

medicaldaily.com7 min
AUG 7
$GILDMedAI 8/10

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences (GILD) reported Q2 2026 non-GAAP loss per share of $6.75 and revenue of $7.8B, both above consensus. Management raised 2026 product sales guidance excluding Veklury to $29.8B-$30.1B and lifted HIV sales growth outlook to 9%-10%. CEO cited HIV and PrEP strength, Trodelvy growth, and ongoing anito-cel launch prep.

zacks.com6 min
AUG 6
$MRKMed

MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

Merck & Co (MSD) and Gilead Sciences ended the Phase III KEYNOTE-D46/EVOKE-03 trial in frontline PD-L1-expressing NSCLC after an external data monitoring committee projected the Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) would not significantly improve overall survival versus Keytruda alone. Trodelvy-Keytruda showed nonsignificant PFS benefit and no new safety issues. Trodelvy Q2 2026 sales rose 26% to $457m.

yahoo.com3 min
AUG 5
$GILDMed

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

Gilead Sciences (GILD) reported Q2 CY2026 revenue of $7.80 billion, up 10.2% year over year, and a non-GAAP loss of $6.75 per share. Full-year revenue guidance was $30.25 billion at the midpoint, 0.6% below analysts’ estimates. Management cited HIV franchise strength, including Biktarvy and PrEP, plus Trodelvy growth, while noting margin pressure from acquisition-related R&D costs.

stockstory.org4 min